Intellia Therapeutics, Inc.

NTLA

$12.70

+0.16%

2026-09-04 12:07:54 EDT+$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes ...

Price Action of NTLA

$12.70

+0.16%+$0.02

High—

Low—

52W High-55.0%

Rel. vol—

Interval

Range2.6h

Volume—SMA5SMA10

—

Key Metrics of NTLA

Snapshot

Latest / TTM · 6 periods

Market Cap

$1.78B

ROCE

-54.4%

EV / EBITDA

-4.45x

+5.3% YoY

FCF Yield

-26.3%

+10.1% YoY

Cash Conversion Cycle

-4.1d

Current Ratio

6.65

Quick take

Financial Highlights of NTLA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

-46.5%

Net Margin

-672.2%

P/E Ratio

-3.77x

n/a

Debt / Equity

0.10

n/a

Current Ratio

6.65

Dividend Yield

0.0%

Understanding

Calendar of NTLA

Upcoming

Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-3.22 · Revenue $50.26M · 13 analysts
Sep 30, 2027
Q3 FY2027 · Estimated results
Est. EPS $-0.71 · Revenue $21.96M · 8 analysts

Financial Statements of NTLA

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of NTLA

Acquisitions (A)

Since Jun 9, 2026

Disposals (D)

Since Jun 9, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Earnings Call Transcript of NTLA

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Hello, and welcome to Intellia Therapeutics Second Quarter Conference Call. My name is Chloe, and I will be your conference operator today. Please be advised that today's call is being recorded. I would now like to turn the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed. Jason Fredette: Thank you, operator, and hello, everyone. Earlier this morning, we issued a press release outlining recent business updates in our second quarter financial results. This document can be found on the Investors and Media section of Intellia's website at intelliatx.com. At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law. Joining me on the call are John Leonard, our Chief Executive Officer; and Ed Dulac, our Chief Financial Officer. With that, I'll now turn the call over to John to begin our business discussion. John Leonard: Thank you, Jason, and good morning, everyone. We're excited to be speaking with you to recap the tremendous progress we made in our Phase III development programs of lonvo-z in hereditary angioedema or HAE, and nex-z in transthyretin amyloidosis or ATTR. The full results of our Phase III HAELO trial in HAE position us very well for a potential approval and launch of the world's first in vivo gene editing product in the first half of next year. We also have gained important new genomic insights that further our understanding of nex-z's profile and could help position us even more favorably within a large and dynamic ATTR market. Let's begin with lonvo-z. Simply put, the second quarter was a momentous period for this program. In April, we reported positive top line results from HAELO and got our rolling BLA submission underway with the FDA. This was followed by our late-breaking oral presentation at EAACI and a concurrent publication in the New England Journal of Medicine, Intellia's sixth manuscript in this prestigious journal. HAELO was an unequivocal success as we achieved statistical significance for the primary and all key secondary endpoints. More specifically, during the 6-month primary observation period, we reported an 87% reduction in mean monthly attacks for lonvo-z versus placebo. 62% of patients were entirely attack-free and therapy-free in the lonvo-z arm. A 23-point improvement was observed for the lonvo-z arm in the total angioedema quality of life score from baseline. For context, a change of just 6 points is considered to be clinically meaningful. The New England Journal manuscript also contained compelling figures and analyses underscoring the unique value proposition that could be …

Leadership Team of NTLA

11 executives

Name	Title	Compensation	Gender	Year Born	Status
Derrick J. Rossi	Founder and Member of Scientific Advisor Board	USD 1,378,345	—	—	Active
Erik J. Sontheimer	Founder and Member of Scientific Advisor Board

Recent News of NTLA

GlobeNewsWire7/30/2026Neutral

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.

Historical Employee Count of NTLA

Current

377

Change

-6.45%

Minimum

377

Maximum

598

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-3.81 vs -3.98	+4.2%	-0.80 vs -0.71	-11.9%
Revenue Surprise	$67.7M vs $56.6M	+19.6%	$7.7M vs $22.0M	-65.1%

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	377	10-K	Feb 26, 2026	View
Dec 31, 2024	403	10-K	Feb 27, 2025	View
Dec 31, 2023	526	10-K	Feb 22, 2024	View
Dec 31, 2022	598	10-K	Feb 23, 2023	View
Dec 31, 2021	485	10-K	Feb 24, 2022	View

Date	Executive	Title	Security	Side	Shares	Price
Aug 21, 2026	LEONARD JOHN M	director, officer: President and CEO	Common Stock	D	2,785	$13.00
Aug 20, 2026	LEONARD JOHN M	director, officer: President and CEO	Common Stock	D	19,890	$12.60
Jul 22, 2026	Dulac Edward J III	officer: EVP, Chief Financial Officer	Common Stock	D	8,111	$11.25
Jul 2, 2026	Dulac Edward J III	officer: EVP, Chief Financial Officer	Common Stock	D	4,677	$18.00
Jul 1, 2026	Dube Michael P	officer: VP, Chief Accounting Officer	Common Stock	D	2,641	$16.78

Intellia Therapeutics, Inc.

Upcoming

FY2026 · Estimated annual results

Q3 FY2027 · Estimated results

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Related stocksBiotechnology

Upcoming

FY2026 · Estimated annual results

Q3 FY2027 · Estimated results

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics

Q4 FY2027 · Estimated results

FY2027 · Estimated annual results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Recent Filings